Fate Therapeutics, Inc. cash flow to debt ratio of -136.27% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Fate Therapeutics, Inc.'s free cash flow has increased -9.36% from $-123.60M last year to $-112.04M, signaling increasing performance

Fate Therapeutics, Inc.'s debt to equity ratio is 0.43, which means that the company's assets are healthy financed, signaling financial stability.

Fate Therapeutics, Inc.'s debt has increased relative to shareholder equity from 0.27 last year to 0.43 today, signaling weakened financials

Fate Therapeutics, Inc. has a net cash position, so leverage is healthy.

Fate Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Fate Therapeutics, Inc.'s profit margin has decreased (50.52%) in the last year from -1.37K% to -2.06K%, signaling decreasing performance

Fate Therapeutics, Inc.'s short-term assets of $208.70M exceed its short-term liabilities of $36.07M

Fate Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Fate Therapeutics, Inc.'s return on equity of -58.89%, is lower than 15.00%, indicating bad performance

Fate Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Fate Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Fate Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Fate Therapeutics, Inc. has negative free cash flow, indicating cash burn

Fate Therapeutics, Inc.'s yearly earnings has increased -26.82% since last year from $-186.26M to $-136.31M, signaling increasing performance

Fate Therapeutics, Inc.'s yearly revenue has decreased 51.24% since last year from $13.63M to $6.65M, signaling decreasing performance

ROIC -53.84% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Fate Therapeutics, Inc.'s 3-year revenue CAGR of -58.98% is negative, indicating declining revenue over the past 3 years

Fate Therapeutics, Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

Fate Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Fate Therapeutics, Inc. has insufficient data to evaluate this check.

Fate Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Fate Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Fate Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Fate Therapeutics, Inc. has insufficient data to evaluate this check.

Fate Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Fate Therapeutics, Inc. has a price-to-book ratio of 1.84x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Fate Therapeutics, Inc. has a price-to-sales ratio of 52.47x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue